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OBJECTIVES In the Intracoronary Stenting and Antithrombotic Regimen-2 trial (ISAR-2), we sought to
investigate the effect of abciximab on angiographic and clinical restenosis after stenting
following acute myocardial infarction (AMI). We also intended to assess the impact of
abciximab on clinical outcome in this setting.
BACKGROUND It is unclear whether abciximab reduces neointima formation after stenting. Such an effect
may be particularly prominent in thrombus-containing lesions.
METHODS Patients undergoing stenting within 48 h after onset of AMI were randomly assigned to
receive either standard-dose heparin or abciximab plus reduced-dose heparin. Of 401 patients
randomized, 366 without 30-day adverse events were eligible for six-month angiographic
follow-up. Scheduled angiography was performed in 80% of these patients.
RESULTS By 30 days, the composite clinical end point of death, reinfarction, and target lesion
revascularization (TLR) was reached in 5.0% of the abciximab group and in 10.5% of the
control group (p 5 0.038). At one year, absolute reduction in the composite clinical end point
by abciximab was still 5.7% but had lost its statistical significance. Our primary end point, late
lumen loss, was 1.26 6 0.85 mm with abciximab and 1.21 6 0.74 mm with standard heparin
(p 5 0.61), and binary angiographic restenosis rates were 31.1% and 30.6%, respectively (p 5
0.92).
CONCLUSIONS In patients undergoing stenting following AMI, abciximab exerted beneficial effects by
substantially reducing the 30-day rate of major adverse cardiac events. During one-year
follow-up, there was no additional benefit from a reduction in TLR nor did abciximab reduce
angiographic restenosis. (J Am Coll Cardiol 2000;35:915–21) © 2000 by the American
College of Cardiology
Glycoprotein IIb/IIIa receptor blockade with abciximab
reduces the early hazard of ischemic complications after
percutaneous coronary interventions by about one-half
(1,2). It is currently unclear whether abciximab offers
additional long-term benefit by reducing neointima formation.
In animal models, platelet deposition and aggregation at
the site of vessel injury promote neointima formation (3–5).
This concept is also supported by the clinical finding of an
association between the PlA polymorphism of platelet gly-
coprotein IIIa and the risk of angiographic restenosis after
coronary stent placement (6). Potent platelet inhibition by
abciximab may reduce neointima formation by blockade of
not only glycoprotein IIb/IIIa but also vitronectin receptors
and Mac-1. These integrins are known to play a key role in
neointima formation (7–9).
Nevertheless, in angiographic studies of in-stent resten-
osis, binary restenosis rates were not reduced by abciximab,
and the effect of abciximab on other indices of neointima
formation was either marginal or absent (10,11). The
inability of abciximab to prevent angiographic or clinical
restenosis in unselected patient populations, however, does
not exclude reduction of neointima formation in specific
groups. For example, in EPISTENT (Evaluation of IIb/
IIIa Platelet Inhibition for Stenting), abciximab markedly
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reduced clinical restenosis rate after stenting in diabetics
(12). Patients with thrombus containing lesions may con-
stitute another group in whom abciximab could be partic-
ularly effective in preventing neointima formation. This is
suggested by animal models of restenosis indicating that the
severity of intracoronary thrombosis after vessel injury
predicts subsequent lumen narrowing (13).
Based on these findings, we hypothesized that potential
inhibition of angiographic or clinical restenosis by abcix-
imab was most pronounced in the most thrombogenic
lesions; that is, in those of acute myocardial infarction
(AMI). We, therefore, conducted the Intracoronary Stent-
ing and Antithrombotic Regimen-2 trial (ISAR-2). This
prospective randomized study on patients undergoing stent-
ing following AMI investigated the effect of abciximab on
angiographic restenosis as the primary end point. In addi-
tion, we assessed the effect of abciximab on clinical resten-
osis and on the composite rate of death, recurrent myocar-
dial infarction and target lesion revascularization (TLR).
METHODS
Study cohort. The study included patients with AMI
undergoing revascularization by stent placement within 48 h
after onset of pain. Inclusion criteria were (a) typical anginal
pain lasting .30 min, (b) ST-segment elevation of at least
1 mm in two or more contiguous leads, (c) elevation in
creatine kinase to at least three times the upper limit of
normal with a concomitant rise in MB isoenzyme, and (d)
coronary artery occlusion with angiographic appearance of
fresh thrombus. We recruited patients who met the first
criterion plus at least one of the other criteria. Exclusion
criteria were inability to give informed consent and contra-
indications to one of the study drugs. All eligible patients
who gave written, informed consent were randomized by
means of sealed envelopes. Patients, but not physicians,
were blinded to the assignment of treatment. The study was
carried out according to the Declaration of Helsinki and was
approved by our institutional ethics committee.
Study protocol. Before catheterization, all patients re-
ceived heparin, 5,000 U, and aspirin, 500 mg, intravenously.
Once the decision was made for stent placement, patients
were randomized to one of two treatment regimens. Pa-
tients assigned to treatment with glycoprotein IIb/IIIa
receptor blockade received a bolus of abciximab, 0.25 mg/kg
of body weight, followed by continuous infusion, 10 mg/min
for 12 h plus an additional dose of heparin, 2,500 U,
intraarterially. In patients assigned to usual care, we admin-
istered heparin, 10,000 U, intra-arterially, followed by IV
heparin infusion, 1,000 U/h, for the first 12 h after sheath
removal. Stent placement was performed as described pre-
viously (14). We used different types of slotted-tube stents,
which were evenly distributed between the study groups
(Table 1). In both groups, postinterventional antithrom-
botic therapy consisted of ticlopidine (250 mg bds) for four
weeks and aspirin (100 mg bds) throughout the study.
During hospital stay, creatine kinase was routinely moni-
tored at intervals of 8 h until it returned to normal or at least
for the first 24 h and daily thereafter. Patients with
successful intervention (TIMI [thrombolysis in myocardial
infarction] flow grade $2, residual stenosis ,25%) and no
adverse cardiac event within the first month were eligible for
angiographic follow-up. Follow-up angiography was per-
formed at six months or earlier if the patient had recurrent
symptoms or signs of ischemia. Patients who had undergone
angiography at ,4 months after recruitment without meet-
ing the criteria for a clinical endpoint were encouraged to
undergo repeat angiography at six months.
Measures of clinical outcome. We monitored major ad-
verse cardiac events, including death, nonfatal reinfarction,
and TLR. Diagnosis of recurrent infarction was based on
typical chest pain, new ST-segment changes and an increase
in creatine kinase of at least 50% over the previous trough
level in at least two samples reaching $240 U/liter. The
TLR was defined as coronary artery bypass surgery (CABG)
or repeat PTCA (percutaneous transluminal coronary an-
giography) involving the stented segment. It was performed
for symptoms or signs of ischemia in the presence of
angiographic restenosis.
Quantitative angiography and definitions. Angiographic
images (Hicor; Siemens) were stored on compact discs and
analyzed off-line by operators unaware of the study groups
to which the patients were assigned. The TIMI flow grades
before and after the intervention were assessed visually.
Quantitative analysis was performed as described previously
(14,15). We obtained minimal luminal diameter (MLD),
reference diameter, percent diameter stenosis and the diam-
eter of the maximally inflated balloon from the analysis
system (MEDIS Medical Imaging Systems, Leiden, The
Netherlands).
Acute gain was calculated as the difference between
post-stenting and predilation MLD, late loss as the differ-
ence between post-stenting MLD and MLD at follow-up,
net gain as the difference between MLD at follow-up and
predilation MLD, and loss index was calculated as the ratio
of late loss to acute gain. Angiographic restenosis was
defined as diameter stenosis .50%.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass surgery
EPISTENT 5 Evaluation of IIb/IIIa Platelet Inhibition
for Stenting
MLD 5 minimal luminal diameter
PTCA 5 percutaneous transluminal coronary
angiography
RAPPORT 5 ReoPro in Acute MI Primary PTCA
Organization and Randomized Trial
TIMI 5 thrombolysis in myocardial infarction
TLR 5 target lesion revascularization
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Study end points. Primary end point was late loss. We also
analyzed other angiographic indices of restenosis, including
loss index, percent diameter stenosis and binary restenosis
rate. To assess clinical restenosis we monitored TLR. In
addition, we assessed clinical outcome by the composite end
point of death, recurrent nonfatal myocardial infarction, and
TLR.
Statistical analysis. According to our previous experience
(16), calculation of sample size was based on the assumption
of a late loss of 1.12 6 0.84 mm (mean 6 SD) in the control
group. We designed the study to detect a 25% reduction in
late loss by abciximab compared with heparin alone, at a
level of significance alpha , 0.05 and a power beta 5 80%.
This assumptions yielded a sample size of 143 patients in
each treatment arm. To account for ineligibility or losses to
follow-up angiography, we intended to include 400 patients.
All data were analyzed on an intention-to-treat basis.
Discrete variables are reported as counts (percentages) and
continuous variables as mean 6 SD. To test differences
between treatment groups for discrete variables, we used the
x2-test or the Fisher exact test as appropriate. Continuous
variables were analyzed by t test for unpaired samples. We
used the Kaplan-Meier method to compute event-free
survival curves and tested differences in treatment effects by
the log-rank test. For all statistical analyses, we used SPlus
4.5 software package; p , 0.05 in the two-tailed test was
regarded as significant.
RESULTS
Study cohort, procedural and clinical outcome. The
study enrolled 401 consecutive patients; 200 were assigned
to usual care and 201 to abciximab treatment. The study
groups were homogeneous with respect to baseline demo-
graphic, clinical and angiographic characteristics (Table 1).
In one patient of the abciximab group and three patients
of the control group, the intervention was unsuccessful. The
reasons were failure to recanalize the infarct-related occlu-
sion and no-reflow (TIMI flow grade 1) despite recanaliza-
tion in two patients, respectively. In 14 patients of the
control group, the operators administered abciximab to
deter imminent failure of the procedure. In 10 of these
patients the intervention was completed with TIMI flow
grade 3. There were no crossovers to higher-dose heparin in
the abciximab group.
At 30-day follow-up, adverse cardiac events were signif-
icantly fewer in the abciximab group than in the usual-care
group, with a relative risk reduction by abciximab of 53%
(Table 2, Fig. 1). The beneficial effect of abciximab affected
all components of the clinical end point almost equally. The
absolute reduction in the incidence of adverse cardiac events
was 5.5% at 30 days. During one-year follow-up, this
absolute reduction persisted (5.7%), but was no longer
statistically significant (Fig. 2). Noncardiac events occurred
at a similar rate in both study groups (Table 2).
Angiographic and clinical indices of restenosis. Lesion
characteristics, technical details of the stenting procedure
and procedural results were comparable in both study
groups (Tables 1 and 3). In particular, MLD after stenting
and acute gain were essentially the same in both groups
(Table 3, Fig. 3).
Among the 397 patients with successful primary inter-
vention, 31 were ineligible for six-month angiographic
follow-up because of adverse events during the first 30 days
(Table 2). In each group, five patients died between 30 days
and scheduled angiographic follow-up. Sixty-four eligible
patients refused repeat angiography. Ultimately, we ob-
tained six-month angiographic follow-up in 80% (292/366)
of the eligible patients. Between the two groups there were
no significant differences in the rate of angiographic
Table 1. Base-Line Demographic, Clinical and Angiographic
Characteristics of the Study Population
Abciximab
(n 5 201)
Usual Care
(n 5 200)
p
Value
Age (yrs) 61.3 6 11.0 60.1 6 12.6 0.32
Women 52 (25.9) 46 (73) 0.50
Active smoker 86 (42.8) 87 (43.5) 0.88
Hypercholesterolemia 92 (45.8) 81 (40.5) 0.28
Arterial hypertension 132 (65.7) 124 (62) 0.44
Diabetes mellitus 35 (17.4) 25 (12.5) 0.17
Multivessel disease 125 (62.2) 116 (85.0) 0.39
Previous PTCA 15 (7.5) 12 (6.0) 0.56
Previous CABG 8 (4.0) 9 (4.5) 0.80
Time from onset of pain
to intervention
0.27
,6 h 75 (37.3) 76 (38.0)
6–12 h 47 (23.4) 33 (16.5)
12–24 h 35 (17.4) 46 (23.0)
24–48 h 44 (21.9) 45 (22.5)
Prior thrombolytic therapy 41 (20.4) 46 (23) 0.52
Killip class 0.80
I 149 (74.1) 150 (75.0)
II 31 (15.4) 27 (13.5)
III 5 (2.5) 8 (4.0)
IV 16 (8.0) 15 (7.5)
TIMI flow grade 0/1 145 (72.1) 137 (68.5) 0.43
Q-wave MI 145 (72.1) 131 (65.5) 0.15
Target vessel 0.20
LAD 84 (41.8) 66 (33.0)
LCX 38 (18.9) 51 (25.5)
RCA 71 (35.3) 77 (38.5)
Venous bypass graft 8 (4.0) 6 (3.0)
Stent type 0.66
InFlow 113 (56.2) 102 (51.0)
Multilink 19 (9.5) 21 (10.5)
Nir 24 (11.9) 20 (10)
Palmaz-Schatz 25 (12.4) 32 (16.0)
PURA-A 20 (10.0) 25 (12.5)
Peak creatine kinase
(U/liter)
1,056 6 1,277 954 6 1,014 0.37
Data are expressed as mean value 6 SD or number of patients (percentage).
CABG 5 coronary artery bypass graft surgery; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery.
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follow-up (p 5 0.80). The median time interval from the
initial intervention was 194 days in the abciximab group and
193 days in the control group (p 5 0.75).
At six-month follow-up, none of the angiographic indices
of restenosis showed a significant difference between the
two treatment groups (Table 3). Specifically, the primary
end point of late loss was similar in both groups (Fig. 3).
Similarly, loss index, net gain and MLD at follow-up were
not significantly different between treatment groups. Binary
restenosis rates were 31.1% in the abciximab group and
30.6% in the control group. Between 30 days and one year,
26 patients of the abciximab group and 27 patients of the
control group required TLR (p 5 0.87).
With respect to the effect of abciximab on angiographic
restenosis rates, stratified analysis according to stent type did
not show any significant interaction between stent type and
abciximab (p 5 0.56). When we removed patients with
crossover to abciximab from the analysis, the point estimate
for angiographic restenosis rate remained essentially un-
changed (30.8%).
DISCUSSION
Our prospective randomized trial investigated the effect of
abciximab on clinical outcome and angiographic restenosis
after stenting following AMI. Compared with the reference
treatment, abciximab reduced the early risk of adverse
cardiac events within 30 days after stenting following AMI
by more than one-half. Abciximab thereby achieved an
absolute reduction in the cardiac event rate of 5.5% during
the acute phase. This reduction in event rate was essentially
maintained during the one-year follow-up. Contrary to our
study hypothesis, we did not find an additional late benefit
from abciximab through inhibition of restenosis develop-
ment. Angiographically, none of the indices of neointima
Figure 1. Cumulative combined frequency of death, reinfarction
and TLR during 30-day follow-up in the two treatment groups.
Table 2. Clinical Events During First 30 Days After Intervention
Abciximab
(n 5 201)
Usual Care
(n 5 200) p Value RR (95% CI)
Any cardiac event 10 (5.0) 21 (10.5) 0.038 0.47 (0.25–0.88)
Death or repeat MI 5 (2.5) 12 (6.0) 0.08 0.41 (0.17–1.00)
Death 4 (2.0) 9 (4.5) 0.16 0.44 (0.17–1.18)
Nonfatal MI* 1 (0.5) 3 (1.5) 0.62 0.33 (0.01–4.09)
TLR 6 (3.0) 10 (5.0) 0.30 0.60 (0.27–1.33)
PTCA 5 (2.5) 9 (4.5) 0.27 0.55 (0.23–1.33)
CABG 1 (0.5) 1 (0.5)
Any noncardiac event 7 (3.5) 9 (4.5) 0.79 0.77 (0.25–2.29)
Cerebrovascular accident 0 0
Surgery at access site 0 0
Blood transfusion 7 (3.5) 9 (4.5) 0.79 0.77 (0.25–2.29)
Data are expressed as number of patients (percentage). CI 5 confidence interval; MI 5 nonfatal reinfarction; RR 5 relative risk;
TLR 5 target lesion reavascularization.
*Occurring at day 11 in the abciximab group and at days 1, 17, and 29 in the usual-care group.
Table 3. Quantitative Angiographic Data
Abciximab
(n 5 148)
Usual Care
(n 5 144) p Value
Vessel size, mm 3.13 6 0.49 3.13 6 0.51 0.98
Before stenting
MLD, mm 0.26 6 0.39 0.28 6 0.41 0.69
Diameter stenosis, % 91.2 6 12.6 91.1 6 12.5 0.92
Balloon-to-vessel-ratio 1.07 6 0.09 1.07 6 0.09 0.96
Inflation pressure, atm 14.4 6 3.0 13.9 6 3.0 0.12
After stenting
MLD, mm 3.04 6 0.47 3.04 6 0.47 0.98
Diameter stenosis, % 5.1 6 6.8 5.1 6 7.6 1.00
Stented length, mm 24.7 6 16.4 22.5 6 12.3 0.19
Number of stents 1.96 6 1.23 1.94 6 1.16 0.88
At follow-up
MLD, mm 1.77 6 0.92 1.82 6 0.86 0.65
Diameter stenosis, % 43.3 6 27.6 41.8 6 24.7 0.63
Restenosis rate, % 31.1 30.6 0.92
(23.6–38.5) (23.0–38.1)
Acute gain, mm 2.77 6 0.62 2.75 6 0.61 0.78
Late loss, mm 1.26 6 0.85 1.21 6 0.74 0.61
Loss index 0.47 6 0.31 0.46 6 0.31 0.94
Net gain, mm 1.51 6 0.94 1.54 6 0.96 0.80
Data are expressed as mean value 6 SD or percentage (95% confidence interval).
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formation suggested an advantage of abciximab over the
reference regimen, and binary angiographic restenosis rates
were virtually identical in both groups. These findings
correspond to similar rates of late (.30 days) TLR in both
study groups.
Benefit of abciximab during the acute phase after stent-
ing following AMI. Our study demonstrated an important
contribution of abciximab to efficient interventional treat-
ment of AMI. Although it lacked power to detect statisti-
cally significant differences between the individual compo-
nents of the clinical end point, it suggests a consistent effect
on each type of adverse cardiac events. Most notably,
abciximab conferred conspicuous 2.5% absolute reduction in
the rate of death. The advantageous effects of abciximab
may be explained by improvement of both large-vessel
patency and microcirculation. In a study comparing abcix-
imab with conventional antithrombotic treatment after
stenting following AMI, we recently showed improved
recovery of coronary microvascular reperfusion with abcix-
imab that was linked to better recovery of contraction in the
area at risk (15). The underlying mechanisms for these
effects may be diminished distal embolization of platelet
aggregates as well as inhibition of direct interaction of
platelets with the reperfused endothelium by abciximab
(7,17–20).
We investigated the effect of abciximab in a cohort that
comprised the entire spectrum of patients with AMI re-
ferred to a tertiary-care hospital within 48 h after onset pain.
Apart from patients with Q-wave AMI within the first 12 h,
our study included patients with non-Q-wave AMI, those
with persistent angina for more than 12 h and those with
failed thrombolysis. Abciximab, thus, improved the 30-day
clinical outcome of stenting in a very broad spectrum of
patients with AMI.
The 53% relative risk reduction by abciximab we found
during the acute phase after stenting following AMI is
similar to the 51% risk reduction reported for abciximab in
plain PTCA following AMI on one hand (21) and to the
51% risk reduction reported for abciximab in stenting in the
absence of AMI on the other hand (22). This consistent
effect of abciximab supports the concept that the benefit
from glycoprotein IIb/IIIa receptor blockade in interven-
tional cardiology is not restricted to a certain device or
coronary syndrome.
Lack of effect on angiographic and clinical restenosis.
To our knowledge, the effect of abciximab on angiographic
or clinical restenosis after stenting following AMI has not
been investigated before. Thus, our study demonstrates for
the first time that the thrombus-containing lesions of AMI
do not constitute a subset in which abciximab inhibits
neointima formation.
The concept that abciximab reduces angiographic resten-
osis rates in specific high-risk subgroups is suggested by the
EPISTENT angiographic substudy. In EPISTENT, dia-
betics assigned to abciximab had a significantly lower target
vessel revascularization at six months than did those as-
signed to placebo, an effect that was absent in nondiabetics
(10,12). Based on published animal experiments (3,5,13),
we hypothesized that thrombus-containing lesions such as
those of AMI may constitute another subgroup in whom
abciximab protects from angiographic or clinical restenosis.
Our findings confirm the concept that patients with AMI
constitute a high-risk subgroup for in-stent restenosis.
Comparing our study with contemporary angiographic
studies on stenting we found a substantially increased
neointima formation. In Evaluation of ReoPro and Stenting
to Eliminate Restenosis, EPISTENT, and BENESTENT
II (10,11,22,23), average late loss was 0.63 to 0.80 mm,
while it was 1.24 mm in our current study. Nevertheless, we
were unable to detect a beneficial effect of abciximab on
angiographic in-stent restenosis. Our primary end point,
late loss, did not show a reduction in neointima formation
by abciximab. None of the other variables of neointima
formation demonstrated superiority of abciximab over con-
trol treatment. Moreover, the angiographic results were
corroborated by nearly identical rates of TLR in both groups
from day 30 to one-year follow-up. Our inability to show an
effect of abciximab on angiographic in-stent restenosis
Figure 2. Event-free survival curves for death, reinfarction and
TLR in the two treatment groups.
Figure 3. Cumulative distribution curves for acute gain and late
loss for the two treatment groups.
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cannot be attributed to limited statistical power because the
observed insignificant treatment effect favors control.
Study limitations. The fact that physicians were not
blinded to the treatment represents a limitation of our study.
Angiographic evaluations, however, were performed by
blinded operators. Thus, bias in the assessment of the
primary end point can be excluded. By the use of a
predefined clinical end point criteria and of strict indications
for TLR, we also minimized bias in the assessment of
clinical outcome.
In some eligible patients we could not obtain angio-
graphic follow-up. This problem affected both study groups
similarly. Previous analyses have shown that reliable esti-
mates of restenosis rates can be obtained with angiography
rates $80% as in our study (24).
In 14 patients of the usual-care group, operators admin-
istered abciximab to deter a detrimental outcome of the
intervention. These crossovers may have attenuated some-
what the observed beneficial effect of abciximab.
Implications. The investigators of the ReoPro in Acute
MI Primary PTCA Organization and Randomized Trial
(RAPPORT) on glycoprotein IIb/IIIa receptor blockade
with PTCA following AMI concluded that “the use of
(these) platelet inhibitors may be particularly valuable in
patients who are not candidates for stenting” (21). Our
study extends the findings of RAPPORT in demonstrating
that the benefit from abciximab following AMI is as
prominent with stenting as it is with plain PTCA. We
found a 53% reduction in 30-day event rates, and although
we did not detect an additional benefit from inhibition of
angiographic or clinical restenosis, there was no appreciable
attenuation of the initial beneficial effect either.
Our studies add weight to the concept that stenting and
glycoprotein IIb/IIIa receptor blockade afford beneficial
synergy (10) in AMI. As shown previously by the Zwolle
group and the PAMI group, stents improve the six-month
clinical outcome compared with PTCA by reducing TLR,
but they have no beneficial effect on the risk of early
complications and even deteriorate the rate of TIMI flow
grade 3 (25,26). In contrast, our studies demonstrate that,
compared with conventional treatment, abciximab enhances
myocardial reperfusion (15) and improves 30-day outcome
after stenting following AMI (this study). Combining the
assets of stenting with those of GP IIb/IIIa receptor
blockade may thus afford a highly efficient reperfusion
strategy.
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